Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

RISK MANAGEMENT ASPECTS FOR QUALITY IN PHARMACEUTICAL DEVELOPMENT

DOI: https://doi.org/10.29296/25877313-2023-03-01
Issue: 
3
Year: 
2023

S.V. Tishkov
Research Scientist, Laboratory of Finished Dosage Forms, Experimental and Technological Department,
Federal State Budget Scientific Institution «Scientific Research Institute of Pharmacology n.a. V.V. Zakusova» (Moscow, Russia)
E-mail: sergey-tishkov@ya.ru
E.V. Blynskaya
Dr.Sc. (Pharm.), Head of the Laboratory of Finished Dosage Forms, Experimental and Technological Department,
Federal State Budget Scientific Institution «Scientific Research Institute of Pharmacology n.a. V.V. Zakusova» (Moscow, Russia)
K.V. Alekseev
Dr.Sc. (Pharm.), Professor, Chief Researcher, Laboratory of Finished Dosage Forms,
Federal State Budget Scientific Institution «Scientific Research Institute of Pharmacology n.a. V.V. Zakusova» (Moscow, Russia)
V.K. Alekseev
Junior Research Scientist,
Federal State Budget Scientific Institution «Scientific Research Institute of Pharmacology n.a. V.V. Zakusova» (Moscow, Russia)

Currently, for the pharmaceutical development of both original and generic drugs, a systematic scientifically based approach is used to create model formulations and dosage form technology. The use of this approach is expressed in the paradigm of Quality-by-Design (QbD) and the application of quality risk management (QRM) methods. The use of these concepts and their deep integration with each other is due to the presence of uncertainty properties in the manifestation of risks that have different degrees of severity of consequences, the probability of occurrence and their detectability. In the case of the use of original pharmaceutical substances, innovative methods or dosage forms, uncertainty increases, and with them the need to use methods for assessing, analyzing, controlling, accepting and communicating risks. The purpose of this article is to analyze the possibilities for introducing the QRM system into the pharmaceutical development process, identify the project field and critical indicators of quality and process, analyze the features and systematize the initial risk assessment methods, in particular risk identification. The article demonstrates possible methods for assessing and managing risks in pharmaceutical development using solid dosage forms as an example, in particular, in terms of such key characteristics as polymorphism, particle size, solubility of pharmaceutical substances, their interaction with excipients, etc. In addition, when considering risk identification methods such as: brainstorming, Delphi method, interviews, documentation review, application of checklists and construction of cause-and-effect diagrams, etc. an assessment of the advantages and disadvantages of the approaches and the main problems characteristic of all QRM methods was carried out.
Keywords: 
quality risk management
pharmaceutical development
risk identification
risk assessment
design space
References: 
  1. ICH Q8. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceu-ticals for Human Use, Geneva, 2005; p. 19.
  2. Food and Drug Administration CDER. Guidance for in-dustry, Q8 (R2) Pharmaceutical Development, Rockville. 2009; p. 25.
  3. International Conference on Harmonization (ICH) of Technical Re-quirements for Registration of Pharmaceuticals for Human Use, Topic Q9: Quality Risk Management, ICH, Geneva. 2009; p. 20.
  4. Quality risk management (ICH Q9). (2011). EMA/INS/GMP/79766/2011. [Электронный ресурс]. URL: http://www.emea.europa.eu/ docs/en_GB/ document_library/ Scientific_guideline /2009/09/ WC500002873.pdf.
  5. International Conference on Harmonization (ICH) of Technical Re-quirements for Registration of Pharmaceuticals for Human Use, Topic Q10: Pharmaceutical Quality System, Geneva. 2011; p. 18.
  6. AS/NZS ISO 31000. Risk management – Principles and guidelines. International Organization for Standardization. 2009. [Электрон-ный ресурс]. URL: http://infostore.sai-global.com/store/Details.aspx?ProductID=1378670.
  7. ISO Guide 73:2009. ISO [Электронный ресурс]. URL: https://www.iso.org/cms/render/live/en/sites/isoorg/contents/data/standard/04/46/44651.html (дата обращения: 20.06.2022).
  8. Блынская Е.В., Тишков С.В., Алексеев К.В. и др. Особенности фармацевтической разработки лиофилизата ГК-2 для паренте-рального применения. Российский биотерапевтический журнал. 2018; 17(4): 81–90.
  9. Venkatesh S., Lipper R.A. Role of the development scientist in compound lead selection and optimization. Journal of pharmaceutical sciences. 2000; 89 (2): 145–154.
  10. Tong W.Q.T. Molecular and physicochemical properties impacting oral absorption of drugs. Biopharmaceutics applications in drug development. Springer, Boston, MA. 2008; 26–46.
  11. Ward S., Chapman C. Transforming project risk management into project uncertainty management. International journal of project management. 2003; 21(2): 97–105.
  12. Duncan W. Project Management Institute. A Guide to the Project Management Body of Knowledge. 2005; p. 598.
  13. Chapman R.J. Simple tools and techniques for enterprise risk man-agement. John Wiley & Sons/Chichester, West Sussex. 2011; p. 637.
  14. Elkington P., Smallman C. Managing project risks: a case study from the utilities sector. International Journal of Project Management. 2002; 20(1): 49–57.
  15. Gangidi P. A systematic approach to root cause analysis using 3×5 why’s technique. International Journal of Lean Six Sigma. 2018; 10(1): 295–310.
  16. Radhakrishnan P., Chacko S. Risk management in pharma-ceutical development: a short review. Asian Journal of Phar-maceutical Research. 2018; 8(3): 185–190.
  17. Aven T. Risk assessment and risk management: Review of recent advances on their foundation. European Journal of Operational Research. 2016; 253(1): 1–13.
  18. Porananond D., Thawesaengskulthai N. Risk management for new product development projects in food industry. Jour-nal of Engineering, Project, and Production Management. 2014; 4(2): 99–113.
  19. Kushner IV J., Langdon B. A., Hiller J. I. et al. Examining the impact of excipient material property variation on drug product quality attributes: a quality-by-design study for a roller compacted, immediate release tablet. Journal of phar-maceutical sciences. 2011; 100(6): 2222–2239.
  20. Abdoh A., Al‐Omari M. M., Badwan A. A. et al. Amlodipine besylate–excipients interaction in solid dosage form. Phar-maceutical development and technology. 2004; 9(1): 15–24.
  21. Serajuddin A.T.M., Thakur A.B., Ghoshal R.N., et al. Selection of solid dosage form composition through drug–excipient compatibility testing. Journal of pharmaceutical sciences. 1999; 88(7): 696–704.
  23. Charoo N.A., Ali A.A. Quality risk management in pharmaceutical development. Drug development and industrial pharmacy. 2013; 39(7): 947–960.
  24. Urben P. (ed.). Bretherick's handbook of reactive chemical hazards. Elsevier. 2017; p. 1502.
  25. Shah V.P., Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413–420, 1995–Backstory of BCS. The AAPS journal. 2014; 16(5): 894–898.
  26. Papadopoulou V., Valsami G., Dokoumetzidis A. et al. Bio-pharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples. International journal of phar-maceutics. 2008; 361(1-2): 70–77.
  27. Rabinow B.E. Nanosuspensions in drug delivery. Nature reviews Drug discovery. 2004; 3(9): 785–796.
  28. Dickinson P.A., Lee W.W., Stott P.W., et al. Clinical re-levance of dissolution testing in quality by design. The AAPS journal. 2008; 10(2): 380–390.
  29. Blessy M., Patel R.D., Prajapati P.N., et al. Development of forced degradation and stability indicating studies of drugs–A review. Journal of pharmaceutical analysis. 2014; 4(3): 159–165.
  30. Liu L., Levin M., Sheskey P. Process development and scale-up of wet granulation by the high shear process. Developing solid oral dosage forms. Academic Press. 2009: 667–699.
  31. Lourenço V., Lochmann D., Reich G., et al. A quality by design study applied to an industrial pharmaceutical fluid bed granulation. European journal of pharmaceutics and biopharmaceutics. 2012; 81(2): 438–447.